µµ¼­Á¤º¸
Á¦¸ñ ÃֽŠ¹ÙÀÌ¿ÀÀǾàÇ°
ÀúÀÚ °­½ÂÈÆ , ¼ÛÁö¿ë, Àü¼öȯ, ÃÖ¿ë¼ö
¿ªÀÚ
ÃâÆÇ»ç È«¸ª°úÇÐÃâÆÇ»ç
ISBN 9791156006695
ÃâÆÇÀÏ 2019³â 05¿ù 20ÀÏ
ÆÇÇü 187 * 258 * 18 mm
ÆäÀÌÁö¼ö 386ÂÊ
ÆǸŰ¡°Ý 29,000¿ø
 Information



 Contents

1Àå ÀǾàÇ°À̶õ ¹«¾ùÀΰ¡? ÇÕ¼ºÀǾàÇ°/¹ÙÀÌ¿ÀÀǾàÇ°
1.1 °³¿ä
1.2 ÇÕ¼ºÀǾàÇ°
1.3 ¹ÙÀÌ¿ÀÀǾàÇ°
1.4 ÀǾàÇ°À¸·Î °®Ãß¾î¾ß ÇÒ Ç°ÁúƯ¼º
1.5 ÀǾàÇ° °³¹ß°úÁ¤(½Å¾à)
1.6 Á¦¾à »ç¾÷ÀÇ Æ¯Â¡
Âü°í¹®Çå

2Àå ÀçÁ¶ÇմܹéÁú(Recombinant Protein)
2.1 °³¿ä
2.2 »çÀÌÅäÄ«ÀÎ(Cytokines)- ÀÎÅÍÆä·Ð ·ù
2.3 »çÀÌÅäÄ«ÀÎ(Cytokines)- ÀÎÅÍ·ùŲ·ù ¹× TNF
2.4 Ç÷±¸¼¼Æ÷»ý¼º ÃËÁøÀÎÀÚ
2.5 ¼ºÀå ÀÎÀÚ·ù(Growth Factors)
2.6 È£¸£¸ó·ù(Hormones)
2.7 Ç÷¾×°ü·Ã Á¦Ç°(Blood Products)
2.8 Ä¡·á¿ë È¿¼Ò(Therapeutic Enzymes)
2.9 ½ÃÀåÇöȲ ¹× Àü¸Á
Âü°íÀÚ·á

3Àå Ä¡·á¿ëÇ×ü(Therapeutic Antibodies)
3.1 °³¿ä
3.2 Ç×ü ¼³°è ½Ã °í·Á»çÇ×(Antibody Design Considerations)
3.3 Ç×üÀÇ ±¸Á¶ ¹× ¿ªÇÒ(Structural and functional features of antibody)
3.4 Ç×ü »ý»ê ±â¼úÀÇ ÁøÈ­(Evolution of antibody technology-Anibody engi-neering)
3.5 ±âŸ Antibody Engineering
3.6 ´ÜÀÏ Å¬·Ð Ç×üÀÇ ÀÓ»óÀû ÀÀ¿ë(Clinical applications of MAbs)
3.7 ½ÃÀ忹Ãø(Market forecast)

4Àå ¹ÙÀÌ¿Àº£ÅÍ(Biobetter)
4.1 °³¿ä
4.2 Áö¼ÓÇü ´Ü¹éÁú ÀǾàÇ° ±â¹Ý±â¼ú(Long acting tecnology)
4.3 °íºÐÀÚ ¹°Áú À¶ÇÕ ±â¼ú(Protin plymer conjugation)
4.4 °ú´çÈ­(Hyper glycosylation) ±â¼ú
4.5 À¶´Ü´Ü¹éÁú(Fusion protein)
4.6 Ç×ü ÀýÆí À¶ÇÕ±â¼ú(Fc fusion)
4.7 ¾ËºÎ¹Î À¶ÇÕ ±â¼ú(albumin fusion)
4.8 Ç×ü È¿·Â Áõ´ë ±â¼ú
4.9 ½ÃÀåÇöȲ ¹× Àü¸Á
Âü°í¹®Çå

5Àå ¹é½Å(Vaccine)
5.1 °³¿ä
5.2 History of Vacicen
5.3 Attributes of a good vaccine(ÁÁÀº ¹é½ÅÀÇ Æ¯Â¡)
5.4 Traditional Vaccine Preparations
5.5 Recombinant vaccine
5.6 Adjuvant Technology
Âü°íÀÚ·á

6Àå ¼¼Æ÷Ä¡·áÁ¦(Cell Therapy)
6.1 °³¿ä
6.2 ü¼¼Æ÷Ä¡·áÁ¦
6.3 Á߱⼼Æ÷Ä¡·áÁ¦
6.4 ½ÃÀåÇöȲ ¹× Àü¸Á
6.5 »ý°¢ÇØ º¼ ¹®Á¦µé
Âü°í¹®Çå

7Àå À¯ÀüÀÚ Ä¡·áÁ¦(Gene Therapy)
7.1 °³¿ä
7.2 À¯ÀüÀÚ Ä¡·áÁ¦ÀÇ ±â¿ø ¹× ÇöȲ
7.3 À¯ÀüÀÚ Àü´Þ ±â¼úÀÇ Á¾·ù
7.4 À¯ÀüÀÚ Ä¡·á ÀÓ»ó ¿¬±¸ ÇöȲ
7.5 ½ÃÀåÇöȲ ¹× Àü¸Á
7.6 »ý°¢ÇØ º¼ ¹®Á¦µé
Âü°í¹®Çå

8ÀåÀçÁ¶ÇմܹéÁú °³¹ß °úÁ¤
8.1 °³¿ä
8.2 »ý»ê ¼¼Æ÷ÁÖÀÇ ¼±Á¤
8.3 »ý»ê ¼¼Æ÷ÁÖÀÇ ±¸Ãà ¹× Æ¯¼º±Ô¸í(Construction of Production Cell Line and
Characterization of Cell Banks)
8.4 Á¦Á¶ °øÁ¤ °³¹ß(Development of Manufacturing Process)
8.5 ´Ü¹éÁú Ư¼º ¿¬±¸(Protein Characterzation)
8.6 Á¦Á¦ ¿¬±¸ ¹× ¾ÈÁ¤¼º ½ÃÇè(Formulation/Stability test)
8.7 Ç°Áú °ü¸®(Quality Control)
8.8 Ç°Áú º¸Áõ(Quality Assurance)
8.9 ÀüÀÓ»ó/ºñÀÓ»ó ½ÃÇè(Preclinicla/Nonclinical Tests)
8.10 ÀÓ»ó ½ÃÇè
8.11 Çã°¡ ÀÚ·á

9Àå ¹ÙÀÌ¿ÀÀǾàÇ°ÀÇ Á¦Á¶°øÁ¤ ¹× Á¦Á¶¼­¸®
9.1 ÀçÁ¶ÇÕ ´Ü¹éÁú/Ä¡·á¿ë Ç×ü Á¦Á¶ °øÁ¤
9.2 ´ÜÀ§°øÁ¤µé(Unit Operations)
9.3 Á¦Á¶ ¼³ºñ(Manufacturing Facilities)

10Àå °øÀå¼³°è ¹× °æÁ¦¼º °ËÅä
10.1 °øÀå¼³°è½Ã ÀϹÝÀûÀÎ °í·Á»çÇ×
10.2 °øÁ¤¼³°è(Process Design)
10.3 ºÎ´ë ½Ã¼³
10.4 ÃÑÃßÇÏÀÚº» ÃßÁ¤(Estimation of total capital investment)
10.5 °æÁ¦¼º °ËÅä(Feasibility Study)
¹®Á¦Ç®ÀÌ


2019-06-10 ¿ÀÈÄ 4:09:37, Á¶È¸¼ö : 2445